CHEMICALLY INDUCED hepatomas and sarcomas in the rat are in general moderately immunogenic, so that significant protection against challenge with viable tumour cells is afforded to animals immunized with attenuated tumour or after resection of tumour (Baldwin, 1973) . In recent studies with an aminoazo-dyeinduced rat hepatoma, D23, it was determined that the immunogenicity of yirradiated cells was abolished by treating the immunizing cells with agents or procedures which destroyed, or at least impaired, the cells' residual metabolic activity Dennick et al., 1979) . These treatments (mild fixation with glutaraldehyde and maintaining the cells at temperatures between 41TC and 4500 for 30 min before inoculation) did not however modify the expression of membrane-associated tumour-specific and alloantigens as detected serologically by a number of test systems. These included indirect membrane immunofluorescence, complement-dependent cytotoxicity and radioisotopic antiglobulin tests, using appropriate syngeneic and allogeneic sera. Such findings are in accord with the fact that isolated rat tumour-antigen preparations (solubilized tumour-membrane extracts or plasma-membrane fractions) are essentially non-protective in immunization and challenge experiments, even though they retain tumour-specific antigenic activity in serological assays (Price & Baldwin, 1974a, b; Price et al., 1978) .
Conversely, acellular antigen prepara- tions from a number of chemically induced murine tumours are immunogenic, and in some cases mice treated with ,ug quantities of antigen are fully immune to tumour-cell challenge. This is particularly exemplified by studies with the 3-methylcholanthrene-induced murine sarcoma, Meth A (e.g. Natori et al., 1978; Law et al., 1978 Since there is this wide difference between the capacity of antigen preparations from the Meth A tumour and the various sarcomas and hepatomas maintained in WAB/Not rats, a study was undertaken to determine whether procedures which abolished the immunogenicity of irradiated rat hepatoma cells modified the immunogenicity of the Meth A sarcoma in a similar manner. The results in Table I t Tumour cells were treated with stated concentrations of glutaraldehyde for 30 min, as described previously . tumour cells was essentially equivalent to that of cells held at 37°C or on ice for 30 min before injection (Table III) . In previous tests, these treatments (glutaraldehyde or mild heat) completely abolished the immunogenicity of irradiated rat hepatoma D23 cells Dennick et al., 1979) . (Tables I and III ; ratio of immunizing cells :challenge cells, 5: 1). Since the difference between these 2 ratios is so great, it would not be expected to be entirely due to quantitative variations in the number of antigenic determinants per cell in rat and murine tumours. A more tenable explanation is that there is a qualitative difference between the murine and rat antigens which may direct the manner in which they are handled and processed by the immunized recipient. An attractive hypothesis is that differences in the presentation or processing of antigen by macrophages may account for the present findings, since it has been proposed that macrophage-mediated sensitization and direct sensitization of lymphocytes represent 2 distinct pathways of induction of cellular immunity, affecting 2 subpopulations of T-cells (Treves, 1978) . This may contribute to the fact that immunization with acellular rat-tumour-specific antigens is accompanied by antibody formation and sometimes enhancement of tumour growth (Price & Baldwin, 1974b; Price et al., 1978; Baldwin et al., 1978) , whereas immunoprotection is the general feature associated with treatment with murine tumour antigens (Natori et al., 1978; Law et al., 1978) . The extension from these studies is therefore to determine whether tumour antigens from the rat are processed differently from those of their murine-tumour counterparts. It is also important to determine whether procedures which modify the processing of isolated rat tumour antigens (such as chemical modification, or incorporation into the plasma membrane of metabolically active but non-proliferating cells) may be accompanied by the acquisition of a capacity to immunize against a viable tumour-cell challenge.
